Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 73190-019

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 73190-019). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (017 18)

Label for Sacubitril and Valsartan Tablets, 24 mg/26 mg film-coated tablets by AvKARE. The label states Rx only and indicates the package contains 180 tablets. Usage directions, storage conditions, and manufacturer details are present along with a barcode and QR code.*

FDA Label Image

1 (017 60)

Packaging label for Sacubitril and Valsartan Tablets 24 mg/26 mg, film-coated tablets. The label indicates a quantity of 60 tablets and includes storage instructions, manufacturer information (AvKARE), and a National Drug Code (NDC) identifier. The label is primarily white with blue and red text accents.*

FDA Label Image

1 (018 18)

Sacubitril and Valsartan Tablets 49 mg/51 mg film-coated tablets label from AvKARE. The label indicates a bottle containing 180 tablets with the active ingredients Sacubitril and Valsartan, specifying the strength as 49 mg/51 mg. Directions for use, storage instructions, and manufacturer information are present, along with a barcode and a QR code for additional product details.*

FDA Label Image

1 (018 60)

Label for Sacubitril and Valsartan Tablets, film-coated oral tablets with strength 49 mg/51 mg, packaged in a bottle of 60 tablets. Labeler is AvKARE. The label includes dosage and storage instructions, a QR code, and an NDC number 73190-018-60.*

FDA Label Image

1 (019 18)

Label for Sacubitril and Valsartan Tablets, 97 mg/103 mg strength, film-coated oral tablets. The package contains 180 tablets and is labeled Rx only. Manufactured by AvKARE with instructions for storage and usage warnings.*

FDA Label Image

1 (019 60)

Sacubitril and Valsartan Tablets film-coated tablet label showing strength 97 mg / 103 mg. The label indicates 60 tablets per bottle, Rx only, and is labeled by AvKARE. Storage instructions and manufacturing details are also visible on the label.*

FDA Label Image

Chem Structure (Sacubitril And Valsartan Tablets 1)

Chemical structure of Sacubitril and Valsartan, showing detailed molecular diagrams of the two active ingredients in their combined tablet formulation.*

FDA Label Image

Figure 7 (Sacubitril And Valsartan Tablets 10)

This image contains two graphs comparing hazard ratios with 95% confidence intervals for Sacubitril and Valsartan versus enalapril and versus valsartan. Both graphs plot hazard ratio on the vertical axis against left ventricular ejection fraction (%) at screening on the horizontal axis, illustrating relative risk across different ejection fractions in the PARADIGM-HF and PARAGON-HF studies.*

FDA Label Image

Figure 1 (Sacubitril And Valsartan Tablets 2)

A graph showing geometric mean ratio and 90% confidence intervals for coadministered drugs relative to a reference. The x-axis represents change relative to reference from 0.5 to 2, and the y-axis lists drugs including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. Data points indicate AUC and Cmax values with error bars.*

FDA Label Image

Figure 2 (Sacubitril And Valsartan Tablets 3)

A forest plot chart depicting the geometric mean ratio and 90% confidence intervals for AUC and Cmax of LBQ657 and Valsartan across different population subgroups including varying degrees of renal and hepatic impairment, age, sex, and race. The x-axis shows change relative to reference values on a scale from 0.5 to 4.*

FDA Label Image

Figure 3a (Sacubitril And Valsartan Tablets 4)

A Kaplan-Meier curve from the PARADIGM-HF study showing time to first occurrence of cardiovascular death or heart failure hospitalizations comparing Sacubitril/Valsartan tablets and Enalapril over approximately 1,260 days. The graph includes cumulative failure rates (%) on the y-axis and time since randomization (days) on the x-axis, with survival trends and number at risk data for each treatment group.*

FDA Label Image

Figure 3b (Sacubitril And Valsartan Tablets 5)

A Kaplan-Meier curve chart illustrating time to occurrence of cardiovascular death in the PARADIGM-HF study over approximately 1,260 days. It compares cumulative failure rates (%) between patients taking Sacubitril Valsartan tablets and those taking Enalapril, with Sacubitril Valsartan showing a lower failure rate. The chart includes hazard ratio (HR 0.80, 95% CI 0.71-0.89) and risk numbers at various time points for both groups.*

FDA Label Image

Figure 3c (Sacubitril And Valsartan Tablets 6)

A Kaplan-Meier curve chart titled 'Time to First Occurrence of Heart Failure Hospitalizations in PARADIGM-HF' comparing cumulative failure rates over time between Sacubitril Valsartan tablets and Enalapril. The x-axis shows time since randomization in days (0 to 1260), and the y-axis shows cumulative failure rate percentages (0 to 40%). The number of patients at risk at various time points is displayed for both groups below the x-axis. The hazard ratio (HR) with 95% confidence interval is shown on the chart.*

FDA Label Image

Figure 4 (Sacubitril And Valsartan Tablets 7)

A forest plot chart comparing the hazard ratios of Sacubitril and Valsartan tablets versus Enalapril across various subgroups such as age, gender, weight, race, region, NYHA class, estimated GFR, diabetes, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, hospitalization for heart failure, time since diagnosis, cause of heart failure, and use of ICD. The chart includes confidence intervals for each subgroup's hazard ratio with a reference line at 1.0.*

FDA Label Image

Figure 5 (Sacubitril And Valsartan Tablets 8)

A line graph depicting total heart failure hospitalizations and cardiovascular death in the PARAGON-HF study. The x-axis shows time since randomization in days, up to 1440 days. The y-axis indicates the mean number of events per 100 patients. Two lines compare events for Sacubitril and Valsartan versus Valsartan alone, with a patient number at risk table below the x-axis.*

FDA Label Image

Figure 6 (Sacubitril And Valsartan Tablets 9)

A forest plot comparing rate ratios with 95% confidence intervals for Sacubitril and Valsartan versus Valsartan across various subgroups by age, gender, race, region, diabetic status, LVEF, AF status, biomarker levels, blood pressure, medication use, ACEI intolerance, eGFR, and NYHA class. Each subgroup is listed alongside event counts and patient numbers, with graphical markers showing relative effect estimates on a horizontal axis ranging from Sacubitril and Valsartan better to Valsartan better.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.